Daily vs. Weekly Semaglutide: Comparing Drug Exposure in Healthy Individuals

Semaglutide, a GLP-1 receptor agonist, is a widely used medication for type 2 diabetes and obesity, typically administered once weekly via subcutaneous injection. While its efficacy and safety are well-established with this regimen, there was a need for understanding if daily subcutaneous administration achieves comparable steady-state drug exposure to the established once-weekly regimen. This study aimed to directly compare these two dosing frequencies in healthy individuals to inform potential alternative dosing strategies.

The study's primary objective was to quantify and compare the steady-state systemic exposure of semaglutide when administered once daily versus once weekly. While the specific numerical results for the area under the concentration-time curves (AUC) from 0 to 168 hours after dosing on day 78 are not detailed in the provided summary, the trial was meticulously designed to determine if a daily regimen could achieve comparable drug levels to the established weekly dose. > The core finding, though not quantitatively specified in this summary, would reveal whether the daily dosing strategy resulted in bioequivalent exposure, higher exposure, or lower exposure compared to the weekly regimen, which is critical for understanding its pharmacokinetic profile. This direct pharmacokinetic comparison, involving 113 healthy subjects, aimed to provide foundational data on how different administration frequencies impact the overall drug availability in the body over time. The absence of specific quantitative data in this summary means we cannot report precise differences or statistical significance (e.g., p-values) between the two dosing frequencies.